Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05848258 · ClinicalTrials.gov registry record · Phase 2
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
A Phase 2 study of Rheumatoid Arthritis, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 380
- Enrollment target
- 20
- Study locations
NCT05848258: Recruiting Phase 2 study of Rheumatoid Arthritis, sponsored by Eli Lilly and Company.
NCT05848258 is a Phase 2 study of Rheumatoid Arthritis that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 380 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05848258, a Phase 2 study of Rheumatoid Arthritis, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 380 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3871801
Study Locations (20)
Other
- CIPREC - Buenos Aires
- Mautalen Salud e Investigación - Buenos Aires
- CENUDIAB - Buenos Aires
- Medicina Reumatológica - San Fernando
- Instituto de Alta Complejidad San Isidro - San Isidro
- Medical Plus - Uherské Hradiště
- CHD Vendee - La Roche-sur-Yon
- CHU Montpellier Lapeyronie Hospital - Montpellier
Florida
- Integrity Clinical Research - Doral
- Advanced Clinical Research of Orlando - Ocoee - Ocoee
- Encore Medical Research - Weston - Weston
- Conquest Research - Winter Park
New York
- Joseph S. and Diane H. Steinberg Ambulatory Care Center - Brooklyn
- Icahn School of Medicine at Mount Sinai - New York
California
- Newport Huntington Medical Group - Huntington Beach
Illinois
- Willow Rheumatology and Wellness PLLC - Willowbrook
Louisiana
- Accurate Clinical Research, Inc - Lake Charles
North Carolina
- Accellacare - Salisbury - Salisbury
Texas
- Accurate Clinical Research, Inc - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What NCT05848258 shows while recruiting
NCT05848258 is an interventional study that assigns participants to a tested intervention. The registered 380 participants enrollment target is mid-sized for trials with a published cap, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05848258 names 20 study sites across 9 states, led by Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05848258 about?
NCT05848258 is a clinical study titled "An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis". The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
What is the current status of trial NCT05848258?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 380 participants. The study started on 2023-05-23. Estimated completion is 2026-07.
What conditions does trial NCT05848258 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT05848258?
The interventions under investigation include: Placebo (DRUG), LY3871801 (DRUG).
Who is sponsoring clinical trial NCT05848258?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05848258 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Louisiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05848258's enrollment target sits among peer trials
380 48th of 197 higher than 150 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI